2,319 research outputs found
Interdisciplinary (retail) research: The business of geography and the geography of business
NoAt the 2005 British Academy of Management conference several well-known economic
geographers, including Neil Wrigley, Gordon Clark, and Susan Christopherson, called
for management researchers to engage with economic geographers on interrelated
geographical and managerial issues in the study of (retail) firms. In this commentary
we reflect upon the present geography -management interface.We begin by considering
the term `interdisciplinary research' and its relationship to any management - geography interface. This is followed by a context-specific discussion of international retailing and the role of research on the retail transnational corporation (TNC) in developing an interdisciplinary agenda. This commentary represents an initial more business and management focused response to the call from geography academics for more/better interdisciplinary research at the geography - management interface
PDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
PCVII COST EFFECTIVENESS OF ADDING NIASPANTO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
DB6 COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR+ INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS
PDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY
PCV31 HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES:AN ANALYSIS FOR SWEDEN
PDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES
PDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE
PCV68 COST-EFFECTIVENESS OF RAISING HDL-CWITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH PERSISTENT DYSLIPIDEMIA IN AUSTRIAN, SWEDISH AND NORWEGIAN SETTINGS
- …